Rare Primary Central Nervous System Tumors in Adults: An Overview
暂无分享,去创建一个
M. J. van den Bent | A. Brandes | D. Frappaz | A. Idbaih | M. Preusser | C. Dehais | F. Bielle | C. Houillier | S. Asioli | P. Hau | E. Franceschi | G. Lombardi | R. Rudà | V. Di Nunno | Paul Clement Lakomý Nicolai Jean-Yves Ville Silvia Ricc Radek El-Hindy Delattre Vuorinen Scoccianti
[1] Myung Jo Kim,et al. Ampullary gangliocytic paraganglioma with lymph node metastasis , 2022, Medicine.
[2] M. Kool,et al. Abstract B73: Second-generation molecular subgrouping of medulloblastoma: An international meta-analysis of Group 3 and Group 4 subtypes , 2020 .
[3] R. Houot,et al. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. , 2020, Neurology.
[4] F. Guaraldi,et al. Peculiar pathological, radiological and clinical features of skull‐base de‐differentiated chordomas. Results from a referral centre case–series and literature review , 2020, Histopathology.
[5] M. J. van den Bent,et al. EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. , 2019, The Lancet. Oncology.
[6] David T. W. Jones,et al. Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations , 2019, Acta Neuropathologica.
[7] Zev A. Binder,et al. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study , 2019, Clinical Cancer Research.
[8] B. Korf,et al. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Teixeira,et al. Papillary Tumor of the Pineal Region: Systematic Review and Analysis of Prognostic Factors. , 2019, Neurosurgery.
[10] Martin Sill,et al. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes , 2019, Acta Neuropathologica.
[11] B. Jonker,et al. A systematic review of outcome in intramedullary ependymoma and astrocytoma , 2019, Journal of Clinical Neuroscience.
[12] M. Berger,et al. Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma , 2019, Acta Neuropathologica.
[13] K. Hoang-Xuan,et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Northcott,et al. Medulloblastoma , 2019, Nature Reviews Disease Primers.
[15] Elizabeth M. Wells,et al. Late Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed Across Three Decades: A Report From the Childhood Cancer Survivor Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Stevens,et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. , 2019, The Lancet. Oncology.
[17] E. Lis,et al. Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy , 2019, Clinical Cancer Research.
[18] L. Mariani,et al. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. , 2019, European journal of cancer.
[19] Hui Zhao,et al. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers , 2019, Acta Pharmacologica Sinica.
[20] D. Brat,et al. The impact of histopathology and NAB2–STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma , 2018, Acta Neuropathologica.
[21] D. Figarella-Branger,et al. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial , 2018, The Lancet. Oncology.
[22] David M. Hyman,et al. BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] H. Gelderblom,et al. Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival , 2018, European Spine Journal.
[24] A. Niemierko,et al. Endocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] David T. W. Jones,et al. Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma , 2018, Nature Communications.
[26] P. Canoll,et al. Pineal region glioblastomas display features of diffuse midline and non-midline gliomas , 2018, Journal of Neuro-Oncology.
[27] N. Tarbell,et al. Quality of life in patients with proton‐treated pediatric medulloblastoma: Results of a prospective assessment with 5‐year follow‐up , 2018, Cancer.
[28] G. Reifenberger,et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. , 2018, Neuro-oncology.
[29] A. D. Dei Tos,et al. Extra-axial chordoma: a clinicopathologic analysis of six cases , 2018, Virchows Archiv.
[30] B. Rocha,et al. A challenging diagnosis , 2018, Medicine.
[31] G. Nielsen,et al. Clinicopathologic characteristics of poorly differentiated chordoma , 2018, Modern Pathology.
[32] David T. W. Jones,et al. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07) , 2018, Neuro-oncology.
[33] Lihua Wang,et al. Comparing children and adults with medulloblastoma: a SEER based analysis , 2017, Oncotarget.
[34] G. Tallini,et al. Clival chordomas: considerations after 16 years of endoscopic endonasal surgery. , 2017, Journal of neurosurgery.
[35] G. Reifenberger,et al. Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup , 2018, The American journal of surgical pathology.
[36] J. Mann,et al. Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial , 2017, Neuro-oncology.
[37] D. Vanel,et al. Parosteal extra-axial chordoma of the second metacarpal bone: a case report with literature review , 2017, Skeletal Radiology.
[38] F. Cavalli,et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. , 2017, The Lancet. Haematology.
[39] T. MacDonald,et al. Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma , 2017, Neuro-oncology.
[40] Karlyne M. Reilly,et al. Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future , 2017, Journal of the National Cancer Institute.
[41] M. Giovannini,et al. The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma , 2017, Journal of Neuro-Oncology.
[42] H. Toledano,et al. Fluorescence Lifetime Imaging Microscopy, a Novel Diagnostic Tool for Metastatic Cell Detection in the Cerebrospinal Fluid of Children with Medulloblastoma , 2017, Scientific Reports.
[43] A. Goldenberg,et al. Intertumoral Heterogeneity within Medulloblastoma Subgroups. , 2017, Cancer cell.
[44] R. Lloyd,et al. WHO classification of tumours of endocrine organs , 2017 .
[45] M. Lopes,et al. Mixed Gangliocytoma-Pituitary Adenoma: Insights on the Pathogenesis of a Rare Sellar Tumor , 2017, The American journal of surgical pathology.
[46] Martin Sill,et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. , 2017, The Lancet. Oncology.
[47] J. Hainfellner,et al. Validation of nuclear STAT6 immunostaining as a diagnostic marker of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma. , 2017, Clinical neuropathology.
[48] F. Gilles,et al. Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data , 2016, Neuro-oncology.
[49] M. Meyerson,et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas , 2016, Neuro-oncology.
[50] D. Frappaz,et al. Pilocytic astrocytomas. , 2016, Handbook of clinical neurology.
[51] N. Ratner,et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. , 2016, The New England journal of medicine.
[52] M. Hassel,et al. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. , 2016, The Lancet. Oncology.
[53] M. Messerer,et al. Gangliocytomas of the sellar region: A challenging diagnosis , 2016, Clinical Neurology and Neurosurgery.
[54] M. Weller,et al. EANO guidelines for the diagnosis and treatment of meningiomas. , 2016, The Lancet. Oncology.
[55] R. Pfeiffer,et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. , 2016, British journal of haematology.
[56] H. Ohgaki,et al. Molecular subgroups of adult medulloblastoma: a long-term single-institution study. , 2016, Neuro-oncology.
[57] Chao Lu,et al. Retrospective study , 2016, Medicine.
[58] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[59] K. Aldape,et al. TERT Promoter Mutations and Risk of Recurrence in Meningioma. , 2016, Journal of the National Cancer Institute.
[60] David T. W. Jones,et al. Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis , 2016, Acta Neuropathologica.
[61] Naoki Kagawa,et al. Prognostic Value of Medulloblastoma Extent of Resection After Accounting for Molecular Subgroup: An Integrated Clinical and Molecular Analysis , 2016, The Lancet. Oncology.
[62] F. Bertucci,et al. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). , 2016, European journal of cancer.
[63] Pieter Wesseling,et al. Papillary Tumor of the Pineal Region: A Distinct Molecular Entity , 2016, Brain pathology.
[64] C. Beier,et al. Chemotherapy increases long-term survival in patients with adult medulloblastoma--a literature-based meta-analysis. , 2016, Neuro-oncology.
[65] B. Yeap,et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. , 2016, The Lancet. Oncology.
[66] R. Soffietti,et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. , 2016, Neuro-oncology.
[67] K. Ohshima,et al. Gliosarcomas arising from the pineal gland region: uncommon localization and rare tumors , 2016, Neuropathology : official journal of the Japanese Society of Neuropathology.
[68] Gary D. Bader,et al. Divergent clonal selection dominates medulloblastoma at recurrence , 2016, Nature.
[69] L. Looijenga,et al. A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours , 2015, British Journal of Cancer.
[70] R. Soffietti,et al. Rare glial tumors. , 2016, Handbook of clinical neurology.
[71] D. Krueger,et al. Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis , 2015, Annals of neurology.
[72] M. Meyerson,et al. BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology , 2015, Acta Neuropathologica.
[73] T. Zhou,et al. Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] Michael C. Rusch,et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] K. Hoang-Xuan,et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. , 2015, The Lancet. Haematology.
[76] Gary D Bader,et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.
[77] T. Mikkelsen,et al. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. , 2015, Neuro-oncology.
[78] T. Pietsch,et al. PTEN mutations and activation of the PI3K/Akt/mTOR signaling pathway in papillary tumors of the pineal region. , 2014, Journal of neuropathology and experimental neurology.
[79] D. Gutmann,et al. Neurofibromatosis type 1: a multidisciplinary approach to care , 2014, The Lancet Neurology.
[80] M. Bremer,et al. Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy. , 2014, International journal of radiation oncology, biology, physics.
[81] M. Maio,et al. A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. , 2014 .
[82] Yan Zhang,et al. Clinical characteristics, immunohistochemistry, and outcomes of 77 patients with skull base chordomas. , 2014, World neurosurgery.
[83] Roland Eils,et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.
[84] R. Packer,et al. Cumulative cisplatin dose is not associated with event‐free or overall survival in children with newly diagnosed average‐risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: Report from the Children's Oncology Group , 2014, Pediatric blood & cancer.
[85] B. Geoerger,et al. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. , 2014, European journal of cancer.
[86] T. Pietsch,et al. Adults with CNS primitive neuroectodermal tumors/pineoblastomas: results of multimodal treatment according to the pediatric HIT 2000 protocol , 2014, Journal of Neuro-Oncology.
[87] B. Geoerger,et al. Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. , 2013, Neuro-oncology.
[88] David T. W. Jones,et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] D. Frappaz,et al. SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. , 2013, Neuro-oncology.
[90] C. Bettegowda,et al. Spinal cord tumours: advances in genetics and their implications for treatment , 2013, Nature Reviews Neurology.
[91] David T. W. Jones,et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein , 2013, Acta Neuropathologica.
[92] J. Myung,et al. Clinicopathological and genetic characteristics of extraventricular neurocytomas , 2013, Neuropathology : official journal of the Japanese Society of Neuropathology.
[93] T. Pietsch,et al. Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. , 2013, European journal of cancer.
[94] K. Pienta,et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing , 2013, Nature Genetics.
[95] T. MacDonald,et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience , 2013, Child's Nervous System.
[96] N. Smoll,et al. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children , 2012, Journal of Clinical Neuroscience.
[97] M. Kieran,et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors , 2012, Pediatric blood & cancer.
[98] M. Kool,et al. Update on molecular and genetic alterations in adult medulloblastoma , 2012, memo - Magazine of European Medical Oncology.
[99] S. Pfister,et al. DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis , 2012, Journal of Neuro-Oncology.
[100] T. Kaley,et al. Temozolomide or bevacizumab for spinal cord high-grade gliomas , 2012, Journal of Neuro-Oncology.
[101] Dominique Figarella-Branger,et al. Recensement national histologique des tumeurs primitives du système nerveux central : résultats généraux sur 40 000 cas, principales applications actuelles et perspectives , 2012 .
[102] D. Figarella-Branger,et al. [French brain tumor database: general results on 40,000 cases, main current applications and future prospects]. , 2012, Neuro-Chirurgie.
[103] D. Frappaz,et al. Utility of Ki67 immunostaining in the grading of pineal parenchymal tumours: a multicentre study , 2012, Neuropathology and applied neurobiology.
[104] M. Berger,et al. Factors associated with seizure freedom in the surgical resection of glioneuronal tumors , 2012, Epilepsia.
[105] Michael N. Edmonson,et al. report from The Children's Oncology Group TARGET Project Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a , 2012 .
[106] F. D. de Sauvage,et al. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. , 2011, Cancer research.
[107] S. Croul,et al. Adult medulloblastoma comprises three major molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] T. Pietsch,et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. , 2011, Neuro-oncology.
[109] T. Pietsch,et al. Abstract 3463: Treatment of young children with localized medulloblastoma by chemotherapy alone: Final results of the prospective multicenter trial HIT 2000 confirming the prognostic impact of histology , 2011 .
[110] Kirsten Schmieder,et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.
[111] E. Thiel,et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. , 2010, The Lancet. Oncology.
[112] U. Jaeger,et al. Primary central nervous system lymphoma: a clinicopathological study of 75 cases , 2010, Pathology.
[113] O. Chinot,et al. Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. , 2010, Neuro-oncology.
[114] K. Aldape,et al. Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. , 2010, Neuro-oncology.
[115] Jie Tang,et al. Prognostic factors for long-term outcome of patients with surgical resection of skull base chordomas—106 cases review in one institution , 2010, Neurosurgical Review.
[116] M. Gilbert,et al. Ependymomas in Adults , 2010, Current neurology and neuroscience reports.
[117] Naoki Ishiguro,et al. A MULTICENTRE STUDY , 2010 .
[118] Carmen L. Wilson,et al. A report from the Childhood Cancer Survivor Study (CCSS): cancer related posttraumatic stress symptoms, depression, anxiety, and chronic pain in adult childhood cancer survivors , 2009 .
[119] T. Naidich,et al. Central Nervous System Lymphoma Characterization by Diffusion‐Weighted Imaging and MR Spectroscopy , 2008, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[120] M. Chamberlain. Temozolomide for recurrent low‐grade spinal cord gliomas in adults , 2008, Cancer.
[121] A. Brandes,et al. Long‐term results of a prospective study on the treatment of medulloblastoma in adults , 2007, Cancer.
[122] C. Haie-meder,et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. , 2007, International journal of radiation oncology, biology, physics.
[123] Michael Buchfelder,et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. , 2007, European journal of endocrinology.
[124] D. Nelson,et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[125] P. Burger,et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] D. Evans,et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes , 2005, Journal of Medical Genetics.
[127] D. Correa,et al. Delayed neurotoxicity in primary central nervous system lymphoma. , 2005, Archives of neurology.
[128] J. Armitage,et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[129] A. Brandes,et al. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro‐Oncologia , 2005, Cancer.
[130] G. Akdemir,et al. Dermoid lesion of the cavernous sinus: case report and review of the literature , 2004, Neurosurgical Review.
[131] D. Rades,et al. Prognostic value of the MIB-1 labeling index for central neurocytomas , 2004, Neurology.
[132] T. G. S. Group,et al. Combined chemotherapy and radiation therapy for CNS germ cell tumors – the Japanese experience , 2001, Journal of Neuro-Oncology.
[133] P. Johnson,et al. Melanotic ganglioglioma of the pineal region , 2004, Acta Neuropathologica.
[134] J. Blay,et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[135] L. Deangelis,et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] K. Inoue,et al. Immunohistochemical analyses of thyroid-specific enhancer-binding protein in the fetal and adult rat hypothalami and pituitary glands. , 2001, Brain research. Developmental brain research.
[137] M. Weller,et al. MRI features of primary central nervous system lymphomas at presentation , 2001, Neurology.
[138] J. Provenzale,et al. Serial MR imaging of pineal cysts: implications for natural history and follow-up. , 2001, AJR. American journal of roentgenology.
[139] M. Costa,et al. TTF-1, a Homeodomain Gene Required for Diencephalic Morphogenesis, Is Postnatally Expressed in the Neuroendocrine Brain in a Developmentally Regulated and Cell-Specific Fashion , 2001, Molecular and Cellular Neuroscience.
[140] A. Wade,et al. Surveillance neuroimaging in childhood intracranial ependymoma: how effective, how often, and for how long? , 2001, Journal of neurosurgery.
[141] M. Chamberlain,et al. Adult medulloblastoma: multiagent chemotherapy. , 2001, Neuro-oncology.
[142] A. Jouvet,et al. Pineal Parenchymal Tumors: A Correlation of Histological Features with Prognosis in 66 Cases , 2000, Brain pathology.
[143] L. Rorke,et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[144] W. Ganz,et al. Primary central nervous system lymphoma in patients with AIDS. , 1997, Neuroimaging clinics of North America.
[145] D. Evans,et al. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[146] K. Takakura,et al. Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. , 1997, Journal of neurosurgery.
[147] G. Reaman,et al. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study. , 1996, Blood.
[148] S. Asa,et al. Gangliocytomas of the sellar region--a review. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[149] L. Rorke,et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. , 1994, Journal of neurosurgery.
[150] E. Housepian,et al. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. , 1969, Radiology.
[151] J. Sneep,et al. With a summary , 1945 .